GX1 fundamentals
An in-depth look to MARKER THERAPEUTICS INC operating, investing, and financing activities
GX1 free cash flow for Q1 24 is -3.56 M EUR. For 2023, GX1 free cash flow was -14.89 M EUR and operating cash flow was -14.89 M EUR.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: EUR
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM